We are live on
!
Find out more
E Fund Management Portfolio holdings
AUM
$4.46B
Turnover
13.19%
This Fund
S&P 500
This Quarter
Est. Return
+11.44%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$194M
(+12%)
Cap. Flow
+$40.5M
Cap. Flow
% of AUM
2.24%
Top 10 Holdings %
Top 10 Hldgs %
63.7%
Holding
392
New
24
Increased
176
Reduced
102
Closed
74
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Futu Holdings
FUTU
|
+$32.5M |
| 2 |
Applied Materials
AMAT
|
+$26.5M |
| 3 |
Apple
AAPL
|
+$13.7M |
| 4 |
Microsoft
MSFT
|
+$11.9M |
| 5 |
NVIDIA
NVDA
|
+$9.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$28.3M |
| 2 |
KE Holdings
BEKE
|
+$13.2M |
| 3 |
TSMC
TSM
|
+$13.2M |
| 4 |
ASE Group
ASX
|
+$7.59M |
| 5 |
iQIYI
IQ
|
+$6.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 39.73% |
| 2 | Technology | 31.74% |
| 3 | Communication Services | 9.52% |
| 4 | Healthcare | 5.08% |
| 5 | Financials | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
301
Ironwood Pharmaceuticals
IRWD
$578M
| $152K | 0.01% |
23,342
-24,755
| -51% | -$175K |
2021 Q1
13 quarters
|
|
302
Arcutis Biotherapeutics
ARQT
$3.62B
| $147K | 0.01% |
15,759
-23,107
| -59% | -$209K |
2024 Q1
1 quarter
|
|
303
Sana Biotechnology
SANA
$680M
| $113K | 0.01% |
20,675
-2,686
| -11% | -$21.4K |
2022 Q1
9 quarters
|
|
304
MannKind Corp
MNKD
$977M
| $111K | 0.01% |
21,279
-13,317
| -38% | -$60.4K |
2021 Q1
13 quarters
|
|
305
Cogent Biosciences
COGT
$5.12B
| $94.2K | 0.01% |
11,173
-22,135
| -66% | -$168K |
2023 Q4
2 quarters
|
|
306
Travere Therapeutics
TVTX
$4.68B
| $91K | 0.01% |
11,071
-17,057
| -61% | -$115K |
2022 Q1
9 quarters
|
|
307
Altimmune
ALT
$428M
| $89.5K | ﹤0.01% |
13,458
-28,251
| -68% | -$208K |
2024 Q1
1 quarter
|
|
308
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $79.9K | ﹤0.01% |
11,194
-13,643
| -55% | -$104K |
2023 Q4
2 quarters
|
|
309
Summit Therapeutics
SMMT
$11.7B
| $78.6K | ﹤0.01% |
10,076
-20,653
| -67% | -$112K |
2024 Q1
1 quarter
|
|
310
Relay Therapeutics
RLAY
$3.57B
| $76.8K | ﹤0.01% |
11,778
-10,152
| -46% | -$69.4K |
2022 Q1
9 quarters
|
|
311
Ocugen
OCGN
$265M
| $75K | ﹤0.01% |
+48,412
| New | +$75.4K |
2024 Q2
0 quarters
|
|
312
Editas Medicine
EDIT
$361M
| $60.9K | ﹤0.01% |
13,051
-25,031
| -66% | -$141K |
2022 Q1
9 quarters
|
|
313
Scilex Holding
SCLX
$19.9M
| $60.7K | ﹤0.01% |
898
| – | – |
2023 Q1
5 quarters
|
|
314
Allogene Therapeutics
ALLO
$453M
| $59K | ﹤0.01% |
25,333
-11,797
| -32% | -$34.8K |
2024 Q1
1 quarter
|
|
315
Anavex Life Sciences
AVXL
$121M
| $57.5K | ﹤0.01% |
13,623
-18,036
| -57% | -$73K |
2022 Q1
9 quarters
|
|
316
Heron Therapeutics
HRTX
$68.5M
| $54.7K | ﹤0.01% |
+15,642
| New | +$48.1K |
2024 Q2
0 quarters
|
|
317
C4 Therapeutics
CCCC
$341M
| $52.1K | ﹤0.01% |
11,280
-28,116
| -71% | -$168K |
2024 Q1
1 quarter
|
|
318
Zentalis Pharmaceuticals
ZNTL
$202M
| $41.6K | ﹤0.01% |
10,177
-3,906
| -28% | -$43.6K |
2022 Q1
9 quarters
|
|
319
DELISTED
Akero Therapeutics
AKRO
| – | – |
-13,899
| Closed | -$351K | – |
|
320
Alector
ALEC
$205M
| – | – |
-13,025
| Closed | -$78.4K | – |
|
321
Align Technology
ALGN
$10.5B
| – | – |
-684
| Closed | -$224K | – |
|
322
DELISTED
Apogee Therapeutics
APGE
| – | – |
-3,125
| Closed | -$208K | – |
|
323
Arcturus Therapeutics
ARCT
$294M
| – | – |
-7,400
| Closed | -$250K | – |
|
324
AutoZone
AZO
$50.5B
| – | – |
-255
| Closed | -$804K | – |
|
325
Baxter International
BAX
$13.1B
| – | – |
-4,788
| Closed | -$205K | – |
|
Similar funds
E Fund Management's Q2 2024 Portfolio in Review
As of Q2 2024, E Fund Management held 392 positions worth $1.81B, up 12% from $1.61B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
E Fund Management's Q2 2024 filing shows 24 new, 176 increased, 102 reduced and 74 closed positions. Its largest new stake was Futu Holdings: 480,000 shares worth $31.5M. The largest sale was Advanced Micro Devices, an estimated $28.3M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.
- E Fund Management's largest Q2 2024 buy was Futu Holdings: 480,000 shares worth $31.5M.
- E Fund Management added most to Applied Materials in Q2 2024, an estimated $26.5M increase.
- E Fund Management's biggest Q2 2024 reduction was Advanced Micro Devices, cutting an estimated $28.3M.
- E Fund Management fully exited Yum China in Q2 2024, selling an estimated $5.17M.
- E Fund Management's ten largest holdings make up 64% of its $1.81B portfolio in Q2 2024.
- E Fund Management opened 24 new positions and closed 74 in Q2 2024.
- E Fund Management's portfolio value rose 12% quarter-over-quarter to $1.81B.
Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.